Lipella Pharmaceuticals Inc. Common Stock (LIPO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lipella Pharmaceuticals Inc. Common Stock (LIPO) has a cash flow conversion efficiency ratio of -1584.949x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.36 Billion) by net assets ($1.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Lipella Pharmaceuticals Inc. Common Stoc (LIPO) market capitalisation for the company's overall valuation and market capitalisation.
Lipella Pharmaceuticals Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Lipella Pharmaceuticals Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Lipella Pharmaceuticals Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lipella Pharmaceuticals Inc. Common Stock ranked by their cash flow conversion efficiency. See cash flow to debt ratio of Lipella Pharmaceuticals Inc. Common Stoc to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Soosung Innovation Co. Ltd.
KQ:084180
|
0.036x |
|
Effector Therapeutics Inc
NASDAQ:EFTR
|
-8.800x |
|
Bank Cimb Niaga Tbk
JK:BNGA
|
0.065x |
|
Carzo Holdings Bhd
KLSE:03048
|
-0.011x |
|
Grom Social Enterprises Inc
NASDAQ:GROM
|
-0.154x |
|
DIH Holdings US, Inc. Class A Common Stock
NASDAQ:DHAI
|
0.089x |
|
IRPC Public Company Limited
F:TPIG
|
0.214x |
|
Data Storage Corporation
NASDAQ:DTSTW
|
0.004x |
Annual Cash Flow Conversion Efficiency for Lipella Pharmaceuticals Inc. Common Stock (2019–2024)
The table below shows the annual cash flow conversion efficiency of Lipella Pharmaceuticals Inc. Common Stock from 2019 to 2024. View Lipella Pharmaceuticals Inc. Common Stoc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.92 Million | $-3.95 Million | -2.058x | -105.45% |
| 2023-12-31 | $3.14 Million | $-3.15 Million | -1.002x | -155.80% |
| 2022-12-31 | $4.68 Million | $-1.83 Million | -0.392x | +43.64% |
| 2021-12-31 | $1.42 Million | $-989.27K | -0.695x | -1026.69% |
| 2020-12-31 | $463.32K | $-28.58K | -0.062x | -118.66% |
| 2019-12-31 | $-118.34K | $-39.12K | 0.331x | -- |
About Lipella Pharmaceuticals Inc. Common Stock
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen plan… Read more